Eli Lilly announced a 170% price increase for its diabetes and weight-loss medication Mounjaro in the UK, raising the list price from $122 to £330 per month's supply of the highest dose. The new pricing is effective from September 2025 and aligns with prices in other European markets. The move follows the launch of Mounjaro in the UK in February 2024, where it initially offered a lower price than in other European regions to ensure timely NHS availability. Sales of Mounjaro have since surpassed those of Novo Nordisk's Wegovy in the UK's online pharmacy market by late 2024.

According to 14 Wall Street research analysts, the average twelve-month stock price target for Novo Nordisk A/S is $83.75, with a high forecast of $160.00 and a low of $54.00. The current stock price is $50.90, suggesting a potential upside of 64.54%. The consensus rating is 'Hold', with 11 hold, 1 sell, and 2 buy ratings. Recent upgrades include BNP Paribas (from 'underperform' to 'neutral'), while Guggenheim and HSBC were downgraded to 'hold'. The stock has shown volatility, with a 12-month high of $139.74 and a low of $45.05. Institutional interest, including from the Ontario Teachers Pension Plan Board, reflects confidence in the company. Analysts cite recent upgrades and developments in diabetes care as bullish factors, while volatility, competition, and economic conditions are noted as bearish concerns. The forecasted upside has decreased from 109.81% to 64.54% over time, and Novo Nordisk has a lower consensus rating than peers, indicating a more cautious outlook.

The Saudi Arabia Diabetes Drug Market is projected to grow from US$773.6 million in 2024 to US$1.33 billion by 2033 at a 6.22% CAGR, driven by rising diabetes prevalence due to sedentary lifestyles, obesity, and government initiatives under Vision 2030. The market is shifting toward advanced therapeutics such as SGLT2 inhibitors, GLP-1 receptor agonists, and biosimilar insulins, which offer improved glycemic control and cardiovascular benefits. Key players including Novo Nordisk, Sanofi, AstraZeneca, Biocon, Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Novartis are active in the market. Government investments in healthcare infrastructure, public awareness campaigns, and policies like a 50% tax on sugary beverages and 100% tax on energy drinks are supporting market expansion. However, challenges remain, including high costs of newer drugs, limited access in rural areas, and low awareness of diabetes symptoms and treatment options. A major development in October 2024 was a deal between NUPCO, Sudair Pharmaceutical, Sanofi, and Novo Nordisk to localize insulin production.

BNP Paribas Exane has upgraded Novo Nordisk's stock rating from Underperform to Neutral, lowering its price target from DKK405.00 to DKK345.00. The firm adjusted its sales and earnings per share forecasts to be 1-9% and 2-17% below consensus, respectively, citing changes in prescription trends, foreign exchange rates, and pricing dynamics. It projects compound annual growth rates of 7% for sales and 8% for EPS, compared to consensus of 9% and 11%. The firm has adopted a more conservative outlook due to semaglutide's loss of exclusivity in 2032. The new price target is based on a net present value calculation using an 8% weighted average cost of capital and 0% growth post-2040, with a bull-bear valuation range of DKK565-250. The upgrade reflects a more balanced risk-reward profile, as a $23 billion free cash flow into perpetuity would be required for a 30% share price upside, compared to Novo Nordisk's FY2025 guidance of $5-7 billion.

The US Centers for Disease Control and Prevention (CDC) reported that over 25% of US adults with diabetes used GLP-1 injectable medications in 2024. These drugs, including Mounjaro from Eli Lilly and Ozempic from Novo Nordisk, are approved for type 2 diabetes management and are also used for weight loss under brand names Zepbound and Wegovy. Usage was highest among adults aged 50–64 at 33.3%, followed by those aged 18–34 at 25.3% and those 65 and older at 20.8%. Hispanic adults had the highest adoption rate at 31.3%, while Asian non-Hispanic adults had the lowest at 12.1%. The data comes from a nationally representative 2024 survey of US adults with diabetes, which included questions on the use of GLP-1 drugs for blood sugar control or weight loss. The drugs work by mimicking a hormone that regulates blood sugar, slows digestion, and promotes satiety. About 31% of insulin users and 28% of oral drug users also used GLP-1 drugs, indicating integration into combination therapies. Drugmakers have faced criticism over high costs, with monthly list prices around $1,000.